All In Biotech

Drug Trial Radar · NCT07647510

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Dec 2028

Study completion Sep 2031

Sponsor

Lead sponsor
Dianthus TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • ClaseprubartDrug

    IV loading dose on Day 1

  • PlaceboDrug

    IV infusion on Day 1

  • ClaseprubartCombination product

    Prefilled syringe containing claseprubart for SC administration

  • PlaceboCombination product

    Prefilled syringe containing placebo for SC administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale ScoreTime frame: Baseline (Day 1) to Week 17

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Pasadena, California · Recruiting

  • Cinical Study Site

    Boca Raton, Florida · Recruiting

  • Cinical Study Site

    Fayetteville, North Carolina · Not yet recruiting

  • Cinical Study Site

    Houston, Texas · Recruiting

  • Cinical Study Site

    Kutaisi, Georgia · Recruiting

  • Clinical Study Site #2

    Tbilisi, Georgia · Recruiting

  • Clinical Study Site #3

    Tbilisi, Georgia · Recruiting

  • Clinical Study Site #4

    Tbilisi, Georgia · Recruiting

  • Clinical Study Site #5

    Tbilisi, Georgia · Recruiting

  • Clinical Study Site

    Tbilisi, Georgia · Recruiting

  • Cinical Study Site

    Dnipro, Ukraine · Recruiting

  • Cinical Study Site

    Vinnytsia, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.